Valink Therapeutics
ActiveDiscovering bispecific antibody drug-conjugates (BsADC) against cancer
What it does
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Its site says now · captured 2026-08-23
Valink Therapeutics |
Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.
Next to it in Healthcare and bio · bispecific antibody drug discovery
- Abalone BioY Combinator W20
We create activating antibodies to treat diseases others can’t.
- Talus BioY Combinator S21
Discovering drugs that target the DNA regulome
- Known MedicineY Combinator S20
Combining 3D cell culture & AI to translate drugs to clinical success
- AlixiaY Combinator W22
Targeting the Tumor Ecosystem to address cancer drug resistance.
- Rosebud BiosciencesY Combinator W22
Growing micro-organs to find new drugs
- Arpeggio BioY Combinator S19
Arpeggio Bio develops drugs targeting transcription factors using AI…
- Intrinsic Medicine (fka Lupa Bio)SOSV SOSV IndieBio 09
Developing the next generation of essential, disease-modifying medicines
- Civetbio500 Global
Provider of biotechnology service intended to accelerate drug discovery for live bio-therapeutics. The company's service includes a microbiota bank, a clinical intervention platform, and core big data technology that powers their bioinformatics pipeline, enabling researchers to characterize the Asian gut microbiome and understand the varying profiles across country regions.